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Plasma levels of IL-6 and TNF-α in patients with
esophageal cancer
Yener AYDIN1, İbrahim KAPLAN2, Yusuf BİLEN3, Çağlar BULUT2, Fatma GENÇ4,
Atila TÜRKYILMAZ1, Atila EROĞLU1

Aim: Cytokines are multifunctional polypeptides synthesized in various cell types. Interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α) are cytokines that have important roles in cancer pathogenesis. In this study, we investigated
the plasma levels of IL-6 and TNF-α in patients with esophageal cancer.
Materials and methods: Forty-three esophageal cancer patients (24 females and 19 males) who were newly diagnosed
and had not yet undergone operation participated in the study. The patients’ average age was 61.03 ± 12.4 years. The
control group, on the other hand, comprised 43 healthy individuals (22 males and 21 females) with an average age of
56 ± 11.3. Forty-one (95.3%) of the patients had symptoms of dysphagia. The second leading symptom was weight loss,
experienced by 32 (74.4%) of the patients. The cancer of 5 (11.6%) of the patients advanced in stage and had distant
metastases (2 involving the lung and 3 involving the liver) at presentation. TNF-α (TNF-α-EASIA Kit, DIAsource) and
IL-6 (IL-6-EASIA Kit, DIAsource) were studied using the enzyme-linked immunosorbent assay (ELISA) method.
Results: The measured TNF-α plasma levels of the patients and the control group were 12.35 ± 9.69 and 4.62 ± 3.06 pg/
mL, respectively (P < 0.0001). The average TNF-α plasma levels of the patients with and without weight loss were 14.95
± 9.96 and 4.77 ± 3.12 pg/mL, respectively (P = 0.044). The average IL-6 plasma level of the esophageal cancer patients
was 60.30 ± 53.15 pg/mL, and the average IL-6 plasma level of the control group was 6.00 ± 3.26 pg/mL (P < 0.0001). The
average IL-6 levels of the patients with and without weight loss were 65.22 ± 43.27 and 12.37 ± 6.80 pg/mL, respectively
(P < 0.0001). There was no statistically significant difference in the IL-6 and TNF-α plasma levels of the patients with
and without distant metastasis.
Conclusion: The results show that IL-6 and TNF-α plasma levels may be utilized as tumor markers for the diagnosis of
esophageal cancer. However, to definitely conclude this, we need further extensive studies.
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Introduction
Esophageal cancer ranks sixth in prevalence among
all cancers worldwide. About 386,000 people die of
this cancer each year (1). Esophageal cancer is one
of the most rapidly progressive diseases and is very
difficult to treat. Regional lymph node involvement or
distant organ metastasis may develop rapidly in this
disease, with early and rapid spread to the esophageal

wall and adventitia. Despite aggressive treatments,
detailed 5-year survival is only as high as 20% (2,3).
Cytokines are multifunctional polypeptides
synthesized from various cell types of the human
body. They have important roles in many processes,
such as the development of humoral and cellular
immune responses, triggering of the inflammatory
response, regulation of hematopoiesis, supervision
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of cellular differentiation and reproduction, and
wound healing. Tumor necrosis factor-α (TNF-α)
and interleukin-6 (IL-6) are cytokines that have
important roles in cellular differentiation and growth
(4-6).
TNF-α is a multifunctional cytokine that is also
named cachexin. It has a homotrimeric structure and
is synthesized from various cell types, especially from
macrophages, monocytes, fibroblasts, endothelial
cells, adiposities, B cells, and some tumor cell types
(7).
The increased IL-6 and TNF-α levels have a role
in the development of cancer in many cancer types.
However, the data are not sufficient to show a possible
relation between esophageal cancer and cytokines
TNF-α and IL-6. In this study, we investigated the
levels of TNF-α and IL-6 in esophageal cancer
patients and compared these with the levels of TNF-α
and IL-6 in the control group.
Material and methods
Selection of the patients
The participants in this study were 43 patients
who were diagnosed with esophageal cancer in
2008 and 2009 (Department of Thoracic Surgery,
Medical Faculty Hospital, Atatürk University) but
had not yet undergone any operation. Diagnosis
was made with esophagoscopy and biopsy. Patients
who had been treated either with chemotherapy or
radiotherapy were excluded from this study. Neither
the patients nor the control group had any chronic
systemic disease, such as hypertension or diabetes
mellitus. Patients treated with any medication were
also excluded. The patients included 24 females and
19 males with an average age of 61.03 ± 12.4 years.
The control group, on the other hand, consisted of
21 females and 22 males (healthy persons) with an
average age of 56 ± 11.3.
The most common symptom observed in the
patients was dysphagia, present in 41 (95.3%) of the
patients. The second most common symptom was
weight loss, present in 32 (74.4%) of the patients.
Meanwhile, 79.1% (32/43) of the patients had
squamous cell carcinoma and 20.9% (9/43) had
adenocarcinoma. The tumor was located in the
proximal third of the esophagus in 2 (4.7%) patients,

in the middle third of the esophagus in 21 (48.8%)
patients, and in the distal esophagus or cardium in
20 (46.5%) patients. Distant organ metastases were
present in 5 of the patients who participated in this
study (11.6%; 3 involving the liver and 2 involving
the lung).
Collection of blood samples and storage
Venous blood samples (2 mL) were collected
from both the patients and controls. The
samples were kept in tubes anticoagulated with
ethylenediaminetetraacetate (EDTA). Blood samples
were centrifuged in 10-18 °C at 2000 rpm for 10
min in an air-conditioned centrifugal machine. The
plasma of the blood samples was kept in Eppendorf
tubes at –80 °C until the analysis time. The specimens
were not dissolved more than once, and the samples
obtained had no hemolysis or lipemia. Before the
analysis, the samples were kept at room temperature
until they dissolved.
TNF-α (TNF-α-EASIA Kit, DIAsource) and IL-6
(IL-6-EASIA Kit, DIAsource) were studied using
the enzyme-linked immunosorbent assay (ELISA)
method.
Statistical analysis
The statistical analysis of the raw data was done with
SPSS 11.0 (SPSS Inc., Chicago, IL, USA). Results
were analyzed using the Mann-Whitney test and are
given as mean ± standard deviation. P < 0.05 shows
statistical significance.
Results
The measured average TNF-α plasma levels of the
patients and the control group were 12.35 ± 9.69
and 4.62 ± 3.06 pg/mL, respectively. The average
TNF-α plasma level of the esophageal cancer patients
was statistically significantly higher than that of the
control group (P < 0.0001).
The average TNF-α plasma levels of the esophageal
cancer patients with and without weight loss were
14.95 ± 9.96 and 4.77 ± 3.12 pg/mL, respectively.
The average TNF-α plasma level of the patients with
weight loss was significantly higher than that of the
patients without weight loss (P = 0.044) (Figure 1).
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The measured average IL-6 plasma levels of the
cancer patients and the control group were 60.30
± 53.15 and 6.00 ± 3.26 pg/mL, respectively. The
average IL-6 plasma level of the cancer patients was
significantly higher than that of the control group (P
< 0.0001).
When we subdivide the cancer patients according
to their symptoms, the measured IL-6 plasma levels
of the patients with and without weight loss were
65.22 ± 43.27 and 12.37 ± 6.80 pg/mL, respectively.
The average IL-6 plasma level of the patients with
weight loss was significantly higher than that of the
patients without weight loss (P < 0.0001) (Figure 3).
There was no statistically significance difference
in the measured average IL-6 plasma levels of the
patients with and without distant organ metastasis
(62.48 ± 25.16 and 60.01 ± 56.47 pg/mL, respectively)
(P = 1.0) (Figure 4).
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Figure 3. IL-6 levels in patients with weight loss (group 1) and
patients without weight loss (group 2).

Discussion
Cytokines play a role in inflammatory response and
cancer pathogenesis. Endogenous cytokines are
abnormally produced in many kinds of malignancy,
either as a server, such as autocrine growth factors,
or as an indicator of the immune response to tumors.
Cytokine deregulation participates in the initiation
and development of malignant processes (8). IL-6 is
a hematopoietic cytokine that enables the growth and
differentiation of tumor cells (9). IL-6 functions via
Janus kinase (JAK) receptors. Many kinds of cancer
development can be halted via hypermethylation
of the receptors of IL-6. Neutrophil activation is
responsible for the increased IL-6 in malignant cases
(9).
A recent study that investigated breast cancer
and cytokines revealed that high serum levels of
cytokines are related to a worse prognosis. It was
detected that IL-6 inhibits proliferation via the
induction of apoptosis in cancer cells and thus
creates DNA fragmentation, which is a characteristic
feature of apoptosis in these cells. In that study, it
was cited that the IL-6 level of breast cancer patients
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Although there was a difference in the measured
average TNF-α plasma levels of the patients with
and without distant organ metastasis (16.44 ± 11.86
and 11.80 ± 9.53 pg/mL, respectively), there was no
statistical significance among the groups (P = 0.967)
(Figure 2).
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Figure 2. TNF-α levels in patients with metastasis (group 1)
and patients without metastasis (group 2).
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Figure 1. TNF-α levels in patients with weight loss (group 1)
and patients without weight loss (group 2).
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Figure 4. IL-6 levels in patients with metastasis (group 1) and
patients without metastasis (group 2).
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was 38.3 pg/mL compared with 2.5 pg/mL in the
healthy control group (10). In the present study, the
IL-6 plasma levels of the esophageal cancer patients
and the control group were 60.03 ± 53.15 and 6.00 ±
3.26 pg/mL, respectively. The IL-6 levels of the cancer
patients were 10 times higher than those of healthy
controls.

were higher than those of nonmetastatic patients,
the difference was not statistically significant. We
included only 5 metastatic patients in the present
study. Because of the small number of patients, a
statistical analysis was not properly done. We suggest
that to get statistically significant results, a higher
number of patients should be included in the study.

The relationship between IL-6 and malignancy
is most commonly investigated in relation to
ovarian cancer. Van der Zee et al. (11) detected that
the origin of IL-6 in ovarian cancer patients was
peritoneal mesenchymal cells and cancer cells. They
also suggested an inverse relationship between the
IL-6 level of cystic fluids and the hemoglobin level.
On the other hand, Watson et al. (12), in a study
that investigated the treatment of tumor cells with
anti-IL-6 antibodies, stated that IL-6 had no effect
on tumor growth. Obata et al. (13) reported that
IL-6 may enhance tumor growth by affecting the
adhesion and migration of the ovarian cancer cells.
In another study that investigated the relationship
between the IL-6 level and the response of ovarian
cancer to chemotherapy, investigators stated that IL-6
levels may have a value in the determination of the
progression of ovarian cancer in early phases of the
disease and during the chemotherapy period (14).

Weight loss is an important feature in cancer
patients. Weight loss is associated with anorexia,
decrease in fat and muscle tissue mass, and
decrease in survival rate. The etiology of cachexia is
multifactorial. Cachexia is commonly accompanied
with hypoalbuminemia. Interestingly, the IL-6
level is inversely related to the serum albumin
levels of lymphoma patients (18). Besides the
preclinical animal studies, other studies showed
that IL-6 decreases the synthesis of hepatic albumin
production. Other cytokines can also contribute to
cachexia. TNF, IL-1, IL-6, interferon-g, and leukemia
inhibitory factor are cytokines that lead to weight
loss (19).

Metastasis of cancer is a complicated process
that involves coordinated cellular effect and the
response of both cancer and normal cells. Metastasis
has several steps: 1) invasion of the stroma, 2)
intravasation of blood vessels, 3) transportation in
vasculature, 4) adhesion and implantation to target
capillaries, 5) extravasations from blood vessels, and
6) proliferation of secondary tumors (15). IL-6 has
a role in steps 1 through 3 of cancer metastasis (15).
Results showed that the IL-6 level has prognostic
significance in patients with colorectal cancer that
has metastases to the liver and lymph nodes (16).
Kemik et al. (9) showed that the serum IL-6 levels
of patients with metastatic-stage colon cancer are
higher than those of patients without metastasis.
De Vita et al. (17), in a study that involved 68
gastrointestinal cancer patients, revealed that the IL-6
level is significantly higher in the patient group than
in the control group and that it further increases up
to 2 times in patients with metastasis. In the present
study, although the IL-6 levels of metastatic patients

Some investigators declared that the IL-6 level
increases in pancreas cancer patients and that this
increase is related to weight loss (20). Falconer
et al. (21) also determined that IL-6 is one of the
components of cachexia due to increased resting
energy expenditure and the presence of acute-phase
response in hypermetabolic pancreas cancer patients.
In these patients, peripheral blood mononuclear cells
spontaneously produce an increased amount of IL-6
(21). In the present study, weight loss was present in
32 (74.4%) of the patients, and the IL-6 levels of the
patients with weight loss were higher than those of
the patients without weight loss.
In another study that involved 62 preoperative
colorectal cancer patients, investigators found that
the IL-6 level was nearly 2 times higher in patients
than in the control group. In this study, patients had
rapid weight loss, sepsis, trauma, and fever, which led
to acute-phase response (22).
TNF-α is one of the most commonly studied
cytokines and is associated with various cancer
types. It enables the destruction of cancer cells and is
secreted from various cell types (23). Previous studies
showed that IL-6 is a regulator of TNF-α activity.
If IL-6 is applied in small amounts, it enhances the
cytotoxic effect of TNF-α on human lymphoma cells.
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This effect is a result of the overexpression of TNF-α
receptors via IL-6 (24).
The exact mechanism of how TNF-α affects
the development of cancer is not known yet. It is
speculated that it plays a role in the development
of cancer via the production of DNA damage and
the inhibition of the DNA repair mechanism. In
addition to this, TNF may produce tumor invasion in
colorectal cancer via c-Src oncogene activation (25).
It was previously reported as a macrophage-derived
serum factor due to its effect of hemorrhagic necrosis
on tumors. The necrotic effect of TNF on tumor cells
is due to the destruction of tumor vasculature rather
than direct effect on tumor cell (6).
The inflammatory cytokine TNF-α, especially
when it is produced from epithelial cells and
stromal components, is an important factor in
the progression of tumor in animal studies (26).
This cytokine is produced from malignant cells of
advanced cancers and is considered a bad prognostic
factor. Epithelial ovarian cancer is one of the cancer
types in which TNF-α production is detected. The
TNF-α level is correlated with increased tumor stage
and expression of the chemokine receptor CXCR4 in
biopsy specimens (27).
Cytokines such as IL-6 and TNF-α have important
roles in the prognosis of breast cancer. Moreover,
IL-6 inhibits the proliferation of cancer cells by the
induction of apoptosis and by DNA fragmentation in
cancer cells, which is characteristic of apoptosis (10).
Several studies conducted on soft tissue tumor,
melanoma, colorectal, prostate, and gastrointestinal
cancer patients showed that IL-6 and TNF-α levels

increased from 2-fold to 10-fold compared with the
levels in control patients. IL-6 is also a pleiotropic
cytokine and is further increased in metastatic
patients. These studies emphasized that IL-6 is
a precursor factor in cancer prognosis and that
TNF-α has clinical importance (16,17,28-31). In the
present study, the TNF-α level was 3 times higher
in esophageal cancer patients than in the control
group. Similar to IL-6, the TNF-α level significantly
increased in patients with weight loss compared to
patients without weight loss. Furthermore, there
was no statistically significant difference in the
TNF-α level between the patients with and without
metastasis.
A study involving 353 nonsmall-cell lung cancer
patients showed that IL-6 is related to bad prognosis
in both African Americans and Caucasians. The
same study showed that IL-10 and IL-12 in African
Americans and TNF-α in Caucasians are related to
survival rates (31).
In summary, the IL-6 and TNF-α levels of
the esophageal cancer patients in our study were
significantly higher than those of the control group.
The IL-6 and TNF-α levels were significantly higher
in patients with weight loss than in patients without
weight loss. This paper is an attempt to contribute
to the still inadequate investigation of the effects of
cytokines on esophageal cancer. We recommend
further extensive investigations on the effects of
cytokines on follow-up, prognosis, and tumor growth
and particularly their direct effect on esophageal
cancer to contribute to the understanding of its
pathogenesis.
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